Our Company

we are committed to our vision of transforming lives and making hope a reality for patients with severe genetic and rare diseases and with cancer.

 

leadership

nick-l

Nick Leschly

chief bluebird

david-d

David Davidson, M.D.

Chief Medical Officer

jeff-w

Jeffrey T. Walsh

Chief Operating Officer

james-d

James M. DeTore

Chief Financial Officer

bio-placeholder

Philip D. Gregory,
D. Phil.

Chief Scientific Officer

jason-c

Jason F. Cole, Esq.

Senior Vice President, General Counsel

board of directors

Daniel S. Lynch – Chairman

Independent

Wendy L. Dixon, Ph.D.

Formerly of Bristol-Myers Squibb Company

Steven Gillis, Ph.D.

Arch Venture Partners

James Mandell, M.D.

Formerly CEO of Boston Children's Hospital

John M. Maraganore, Ph.D.

Alnylam Pharmaceuticals

David P. Schenkein, M.D.

Agios Pharmaceuticals

Mark Vachon

Formerly of General Electric

Nick Leschly

chief bluebird

scientific advisory board

Philippe Leboulch, M.D.

Malcolm K. Brenner, M.B., Ph.D.

Mitchell H. Finer, Ph.D.

Stephen P. Goff, Ph.D.

R. Keith Humphries, M.D., Ph.D.

Christof von Kalle, M.D., Ph.D.

Philip Reilly, M.D., J.D.

Andrew M. Scharenberg, M.D.

Philippe Leboulch, M.D.

Co-Chair of Scientific Advisory Board; Head of the Institute of Emerging Diseases and Innovative Therapies of CEA and INSERM; Professor of Medicine, University of Paris; and Visiting Professor, Harvard

Philippe Leboulch is a scientific founder of bluebird bio. He serves as the co-chairman of its Scientific Advisory Board and leader of the LentiGlobin® project. He is a professor of medicine and cell biology at the University of Paris and visiting professor at Harvard Medical School. Philippe is also the director of the Institute of Emerging Diseases and Innovative Therapies of the CEA near Paris and director of an INSERM research unit. He maintains a research laboratory in the genetics division of the Brigham & Women’s Hospital at Harvard Medical School, where he previously served as a full-time faculty member for 15 years after a postdoctoral fellowship at MIT. Philippe is an expert in vectorology and hematopoietic gene therapy, with special emphasis on the beta-hemoglobinopathies. He has been published extensively in high-impact journals and is a regularly invited speaker at major international conferences. Philippe was a member of the Editorial Board of Blood, the Journal of the American Society of Hematology. He has served on major committees of the National Institutes of Health and the American Society of Gene Therapy. Philippe has received numerous NIH grant awards and prizes that include the Grand Prize Etancelin of the French National Academy of Sciences.

Malcolm K. Brenner, M.B., Ph.D.

Malcolm Brenner is a professor in the departments of pediatrics and medicine, section of hematology-oncology at Baylor College of Medicine. He is also director of the Center for Cell and Gene Therapy, which was established by Baylor College of Medicine, The Methodist Hospital and Texas Children’s Hospital. Malcolm’s main research interest is in the field of tumor immunology. He has compared the relative immunostimulatory and anti-tumor potency of autologous and allogeneic tumor vaccines in children with advanced neuroblastoma and in adults with acute and chronic leukemia. Recipients of both autologous and allogeneic vaccines showed evidence of local immunity, but the autologous vaccine showed more potent systemic activity. Similar studies are also underway in patients with acute and chronic leukemia. His laboratory is also using molecular techniques to increase the effectiveness of cytotoxic T cell killing of tumor cells. Malcolm is an associate editor of Blood and of Molecular Therapy, and he is the principal investigator or co-investigator on five National Institutes of Health grants. Malcolm earned his Ph.D., M.B.Ch.B. and B.A. from Cambridge University in England. He completed a fellowship at the Royal College of Pathologists and the Royal College of Physicians.

Mitchell H. Finer, Ph.D.

Mitchell H. Finer, Ph.D., served as bluebird’s chief scientific officer from March 2010 to July 2015. Prior to joining us, Dr. Finer served as senior vice president of development and operations for Novocell, Inc. (now ViaCyte, Inc.), a stem cell engineering company researching treatments for diabetes and other chronic diseases from November 2008 through March 2010. From July 2005 through November 2008, Dr. Finer served as chief executive officer of Intracel Holdings LLC. From June 2003 to June 2005, he held the position of president and chief executive officer of Genteric Inc., or Genteric. Previously, he had served as Genteric’s chief scientific officer from November 2002 to June 2003 and as vice president of research and development for the Gencell division of Aventis Pharma (now Sanofi) from April 2002 to November 2002. He was also a founder and vice president of research for Cell Genesys Inc., and a founder of Abgenix, Inc. and Avalanche Biotechnologies, Inc. Dr. Finer received his B.A. in biochemistry and bacteriology from the University of California at Berkeley and his Ph.D. in biochemistry and molecular biology from Harvard University. He completed a postdoctoral fellowship at the Whitehead Institute for Biomedical Research.

Stephen P. Goff, Ph.D.

Stephen P. Goff is Higgins Professor of biochemistry and molecular biophysics and professor of microbiology at Columbia University College of Physicians and Surgeons. He is also an investigator at Howard Hughes Medical Institute. Stephen’s research at HHMI focuses on the retrovirus, which he started studying during his postdoctoral fellowship in the Massachusetts Institute of Technology laboratory of David Baltimore. He is interested in the replication of retroviruses, and the cellular gene products that interact with these viruses. Stephen is particularly proud of his identification in 1980 of the abl oncogene from the Abelson virus and, later, of its counterpart in the normal DNA of a mouse chromosome. Abl was one of the first oncogenes discovered. Stephen earned an A.B. in biophysics from Amherst College and his Ph.D. in biochemistry from Stanford University.

R. Keith Humphries, M.D., Ph.D.

Keith Humphries is distinguished scientist and director of Terry Fox Laboratory and a professor of medicine at the University of British Columbia (UBC). He is an associate member of Pathology and Laboratory Medicine and Medical Genetics at UBC, is program project group leader of the Terry Fox Foundation of Canada and director of Transgenic and Gene Targeting Facility, BCCA. One of Keith’s research focuses is directed towards the development of improved gene transfer methods to primitive hematopoietic stem cells with the goal of improving approaches for gene function studies and gene therapy. This work includes a major emphasis on developing strategies for gene therapy of inherited anemias such as Thalassemia and sickle cell disease. Novel approaches for non-viral mediated gene transfer to hemopoietic cells are also being explored by utilizing cre/lox recombination methodology.

Christof von Kalle, M.D., Ph.D.

Christof von Kalle serves as a member of the scientific advisory board for bluebird bio and for GATC Biotech AG. He is chairman of the department of translational oncology at the German Cancer Research Center and director of the National Center for Tumor Diseases at the University Hospital Heidelberg. Christof is an adjunct professor of pediatrics at the Cincinnati Children’s Hospital Medical Center, Division of Experimental Hematology, and is a group leader in the section of hematopoiesis and gene transfer at the Institute for Molecular Medicine and Cell Research at the University of Freiburg. He is also a senior clinical investigator of the Gene Therapy Program, and senior medical staff fellow of the Department of Internal Medicine, at the University of Freiburg Medical School in Germany. Christof is world-renowned for his research in the areas of gene therapy for human hemoglobinopathies, retrovirus-mediated therapy of hematopoietic stem cells and clinical hematopoietic stem cell transplantation. He participated in the 1999 French gene therapy trial that restored the immune systems of nine of 11 boys with X-linked severe combined immunodeficiency disease, making this the first clear success in gene therapy. Christof received his M.D. and Ph.D. from Cologne University Medical School.

Philip Reilly, M.D., J.D.

Phil Reilly is a venture partner at Third Rock Ventures in Boston, Mass. He joined Third Rock in 2009 and supports the firm’s founding and advancement of new ventures, with a particular focus on nurturing and growing transformational companies dedicated to breakthrough treatments for genetic disorders. Phil is an accomplished entrepreneur and has a long-standing interest in genetic testing and developing new therapies for genetic diseases. He served as interim chief medical officer of bluebird bio in 2010 and previously served on the board of directors of the American Society for Human Genetics. Phil is currently a trustee of Cornell University and is a founding fellow of the American College of Medical Genetics. In 2000 and 2003, he served as president of the American Society of Law, Medicine and Ethics. Phil has held numerous teaching positions at Tufts University School of Medicine, Harvard Medical School and Cornell University, as well as adjunct professor of both legal studies and biology at Brandeis University. He currently serves on the board of Edimer Pharmaceuticals. Phil holds an M.D. from Yale University and a J.D. from Columbia University. He is a member of the Massachusetts Bar and is board certified in internal medicine and clinical genetics.

Andrew M. Scharenberg, M.D.

Andrew M. Scharenberg is a professor of pediatrics, adjunct in immunology at the University of Washington School of Medicine and co-director of the Program for Cell and Gene Therapy at Seattle Children’s Hospital. Andrew’s laboratory at Seattle Children’s has been at the forefront of developing and translating technologies for gene editing and gene repair. He and his colleagues developed the megaTAL monomeric nuclease platform and have pioneered the co-expression of accessory factors with nucleases for controlling the processing of nuclease-induced DNA double strand breaks. His laboratory is now focused on refining and translating gene editing technologies for treating human hematopoietic genetic disease. Andrew earned a B.S. in biochemistry from Indiana University and an M.D. from the University of North Carolina School of Medicine. He is principal investigator on numerous NIH grants including past principal investigator and co-director of the Northwest Genome Engineering Consortium, and also past co-founder of Pregenen, a pioneering gene editing biotechnology company acquired by bluebird bio in 2014.

Daniel S. Lynch – Chairman

Independent

Daniel S. Lynch has served as chairman of our board of directors since May 2011, when he joined Third Rock Ventures as an entrepreneur-in-residence. Since October 2007, Mr. Lynch has advised and served as executive chair or member of the board of directors for a number of private biopharmaceutical companies, including Stromedix, Inc. (until its acquisition by Biogen Idec in February 2012), Avila Therapeutics, Inc. (until its acquisition by Celgene Corporation in February 2012), RaNA Therapeutics, Inc., Nimbus Discovery, LLC, Edimer Pharmaceuticals, Ember Therapeutics, Inc. and Blueprint Medicines, Inc. He serves on the board of directors of BIND Biosciences, Inc. and Eleven Biotherapeutics, Inc. Previously, Mr. Lynch served as chief executive and chief financial officer of ImClone Systems Corporation, or ImClone. As ImClone’s chief executive officer, he led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. As its chief financial officer, Mr. Lynch led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December 2010, when it was acquired by McKesson. Mr. Lynch received his B.A. in mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.

Wendy L. Dixon, Ph.D.

Formerly of Bristol-Myers Squibb Company

Wendy L. Dixon, Ph.D., has served as a member of our board of directors since April 2013. In 2012, Dr. Dixon was a principal at Great Meadow Consulting LLC and in 2010, she served as senior advisor at The Monitor Group. Since 2005, Dr. Dixon has advised and consulted, and in some instances served as a member of the board of directors, for a number of biopharmaceutical companies, including Alkermes PLC, Incyte Corporation, Orexigen Therapeutics Inc., Furiex Pharmaceuticals, Inc. and formerly Ardea Biosciences, Inc. (sold to AstraZeneca PLC in 2012) and Dentsply International. Dr. Dixon also served as chief marketing officer and president of global marketing for Bristol-Myers Squibb and as a member of the CEO’s Executive Committee from 2001 to 2009. She has had an over 30-year career in the pharmaceutical and biotechnology business, combining a technical background and experience in drug development and regulatory affairs with commercial responsibilities in building and leading organizations and launching and growing more than 20 pharmaceutical products including Tagamet, Fosamax, Singulair, Plavix, Abilify, Reyataz and Baraclude. From 1996 to 2001, she was senior vice president marketing at Merck and prior to that she held executive management positions at West Pharmaceuticals, Osteotech and Centocor, and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon received her B.Sc., M.Sc. and Ph.D. from the University of Cambridge (UK).

Steven Gillis, Ph.D.

Arch Venture Partners

Steven Gillis, Ph.D., has served as a member of our board of directors since April 2011. Since 2005, Dr. Gillis has been a managing director at Arch Venture Partners, a venture capital firm. From 1994 to 2005, Dr. Gillis served as chief executive officer and chairman of the board of directors of Corixa Corporation, which he co-founded in October 1994. Previously, Dr. Gillis served as a director, head of research and development, chief scientific officer and acting chief executive officer of Immunex Corporation, which he co-founded. As a former director and chairman of Trubion Pharmaceuticals, Inc., Dr. Gillis led its acquisition by Emergent BioSolutions in the fall of 2010. Dr. Gillis currently serves as a director of Shire plc, Accelerator Corporation, Acylin Therapeutics Corp., Allozyne, Inc., Oncofactor Corp., Pulmatrix, Inc., VLST Corporation and VBI Vaccines and serves as director and chairman of VentiRX Pharmaceuticals, Inc., Theraclone Sciences, Inc., Lycera Corp. and PhaseRx, Inc. Dr. Gillis received his B.A. in biology and English from Williams College and his Ph.D. in biological science from Dartmouth College.

James Mandell, M.D.

Formerly CEO of Boston Children's Hospital

Dr. James Mandell has served as a member of our board of directors since January 2014. Dr. Mandell became chief executive officer of Boston Children’s Hospital and Children’s Medical Center on October 1, 2000, retiring from the position in October 2013. During his tenure, Dr. Mandell was a member of the board of trustees and professor of surgery at Harvard Medical School. Prior to joining Children’s, he served as dean of Albany Medical College and professor of surgery and pediatrics. Dr. Mandell was promoted from chief of urology to dean of Albany Medical College in l996. He also served as executive vice president for health affairs at Albany Medical Center and executive medical director of Albany Medical Center Hospital. Prior to his tenure at Albany Medical College, he was a member of the medical staff at Children’s Hospital for nine years, advancing to an associate in surgery with an associate professor appointment at Harvard Medical School. Dr. Mandell serves on the board of the Franciscan’s Hospital for Children and as chair of the board of the Harvard Risk Management Company. In addition to a medical degree from the University of Florida College of Medicine, Dr. Mandell holds a master’s in Health Systems Management from Union College, New York.

John M. Maraganore, Ph.D.

Alnylam Pharmaceuticals

John M. Maraganore, Ph.D., has served as a member of our board of directors since January 2012. Since December 2002, Dr. Maraganore has served as the chief executive officer and as a director of Alnylam Pharmaceuticals, Inc. From December 2002 to December 2007, Dr. Maraganore served as president of Alnylam. From April 2000 to December 2002, Dr. Maraganore served as senior vice president, strategic product development with Millennium Pharmaceuticals, Inc. Before Millennium, he served as director of molecular biology and director of market and business development at Biogen, Inc. (now Biogen Idec, Inc.). Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and The Upjohn Company. Dr. Maraganore is also chairman of Regulus Therapeutics, Inc. and a director for Agios Pharmaceuticals and Tempero Pharmaceuticals. In addition, he is an advisor to Third Rock Ventures. He is also a member of the Immunology Advisory Council of Harvard Medical School and a member of the Biotechnology Industry Organization Board. Dr. Maraganore holds a B.A. in biological sciences from the University of Chicago and an M.S. and a Ph.D. in biochemistry and molecular biology from the University of Chicago.

David P. Schenkein, M.D.

Agios Pharmaceuticals

David P. Schenkein, M.D., has served as a member of our board of directors since April 2013. Since August 2009, Dr. Schenkein has served as the chief executive officer of Agios Pharmaceuticals. From April 2006 to July 2009, Dr. Schenkein served as senior vice president of oncology development and Genentech. Dr. Schenkein is also a director for Agios Pharmaceuticals, Foundation Medicine and Blueprint Medicines. Dr. Schenkein received his B.A. in chemistry from Wesleyan University and his M.D. from Upstate Medical School.

Mark Vachon

Formerly of General Electric

Mark Vachon has served as a member of our board of directors since July 2014. Mr. Vachon has assumed a variety of leadership positions across the General Electric organization over 30 years and was a company officer since 1999. Mr. Vachon was president and CEO of GE Healthcare Americas from 2009 to 2010, and prior to that, he was president and CEO of Global Diagnostic Imaging, GE Healthcare, between 2006 and 2009. Between 2003 and 2006, Mr. Vachon was executive vice president and CFO at GE Healthcare. Currently, Mr. Vachon is leading an environmentally focused initiative by GE as vice president of ecomagination. Mr. Vachon serves on the board of Northeastern University. Mr. Vachon holds a B.S. in finance from Northeastern University.

Nick Leschly

chief bluebird

Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals (AGIO), Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, Inc., leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Industry Organization.

nick-l

David Davidson, M.D.

Chief Medical Officer

David Davidson, M.D., has served as our chief medical officer since February 2012. Prior to joining us, Dave served as a senior medical director at Genzyme Corporation, or Genzyme, where he led clinical research for programs in Phases I through IV across a wide range of therapeutic areas for more than a decade. Most recently, Dave was the medical leader for Genzyme’s gene therapy and Pompe disease enzyme replacement therapy programs. In addition to Dave’s translational medicine experience, he has also worked on a number of commercial products, including Fabrazyme and Myozyme/Lumizyme, and was integral in crafting the new drug application that resulted in the approval of Welchol. Prior to Genzyme, Dave was a medical director at GelTex Pharmaceuticals Inc., he completed clinical and research fellowships in infectious diseases at the Harvard Longwood Combined Infectious Diseases Program, and received his B.A. from Columbia University and his M.D. from New York University School of Medicine. In addition, he completed an internal medicine internship, residency training and an endocrinology research fellowship at the University of Chicago Hospitals.

david-d

Jeffrey T. Walsh

Chief Operating Officer

Jeff Walsh has served as our chief operating bluebird since May 2011. Jeff has 25 years of experience in executive leadership positions with responsibility for finance, business development, commercial and business operations, strategic planning and legal functions with established and emerging public and private life sciences companies. From November 2008 to February 2011, Jeff served as chief business officer of Taligen Therapeutics, Inc. where he played a key role in the growth of the company and the ultimate sale of Taligen Therapeutics, Inc. to Alexion Pharmaceuticals, Inc. in January 2011. Jeff started his career at SmithKline Beecham Corporation in finance and worldwide business development roles. He subsequently held senior business development, finance, sales and operations roles at PathoGenesis Corp. (PGNS acquired by Chiron Corporation), Allscripts Healthcare Solutions Inc. (MDRX), EXACT Sciences Corporation (EXAS) and Inotek Pharmaceuticals Corp (ITEK). Jeff received his B.A. in sociology and economics from Yale University and his MBA from the Kellogg Graduate School of Management at Northwestern University.

jeff-w

James M. DeTore

Chief Financial Officer

James M. DeTore has served as our chief financial officer and treasurer, since November 2014. Prior to joining us, Jim served as vice president, corporate finance of Ironwood Pharmaceuticals, Inc. from February 2010 to November 2014, as vice president, finance of Ironwood from June 2006 to January 2010 and as corporate controller of Microbia, Inc. (Ironwood’s predecessor company) from October 2003 to May 2006. From May 1995 through September 2003, Mr. DeTore held financial positions of increasing responsibility at Genzyme Corporation. Jim received his B.S. in finance and an MBA from Northeastern University.

james-d

Philip D. Gregory,
D. Phil.

Chief Scientific Officer

Philip D. Gregory, D. Phil., has served as our chief scientific officer since June 2015. Philip was formerly with Sangamo BioSciences, where he held multiple leadership positions over a nearly fifteen-year tenure, most recently serving as chief scientific officer and senior vice president, research. In this role, he was responsible for the scientific direction and strategic research planning for the company. Philip played an integral role in Sangamo’s partnerships and drove early discovery and development for several IND candidates in multiple therapeutic areas. Prior to joining Sangamo, he was a postdoctoral fellow at Ludwig-Maximilians-Universität München. Philip holds a D. Phil in biochemistry from Oxford University, Keble College and a B.Sc. in microbiology from Sheffield University.

bio-placeholder

Jason F. Cole, Esq.

Senior Vice President, General Counsel

Jason Cole has served as our senior vice president, general counsel since March 2014. Prior to joining us, Jason served as executive vice president, corporate development and general counsel at Zalicus Inc. from September 2011 through March 2014, and as senior vice president, general counsel of Zalicus, and its predecessor company CombinatoRx, Inc. from January 2006 to September 2011. From 1999 to 2006, Jason was a corporate and securities attorney at Ropes & Gray LLP. Mr. Cole holds an A.B. in government from Dartmouth College and a J.D. from Columbia University School of Law.

jason-c